Cosmo Pharmaceuticals N.V., NL0011832936

Cosmo Pharmaceuticals N.V., NL0011832936

26.05.2023 - 17:34:42

Aktion?rinnen und Aktion?re von Cosmo Pharmaceuticals stimmen an der Generalversammlung allen Traktanden zu

Kontakt Hazel Winchester, Head of Investor Relations Cosmo Pharmaceuticals N.V.?? ??? ??? ? Tel: +353 1 817 03

Juristischer Hinweis (in englischer Sprache) Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Cosmo and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.

Ende der Medienmitteilungen

Sprache: Deutsch Unternehmen: Cosmo Pharmaceuticals N.V. Riverside 2, Sir John Rogerson?s Dublin 2 Dublin

Irland Telefon: + 353 1 817 0370 E-Mail: Internet: ISIN: NL0011832936 B?rsen: SIX Swiss Exchange EQS News ID: 1643475 ? Ende der Mitteilung EQS News-Service